Novo Nordisk, the Danish pharmaceutical firm behind Ozepic and Wegovy, restricted to some extent the tumultuous 2024, bearing in mind revenue and income on Wednesday, which conveniently gained Wall Road’s expectations. However the drug creator mentioned he anticipated gross sales development to decelerate in 2025 as competitors was rising.
Novo nordisk retains its title as the most precious company in EuropeHowever the value of his shares has dropped by about 40 %, as final June reached its peak, as analysts are nervous in regards to the uncertainty about looking for medicines for weight problems and the implementation of recent medicine within the exams.
“Final yr was a story of two halves,” says Emily Subject, an analyst at Barclays. The primary half of 2024 supplied “very total pleasure”.
However then the information recommend that weight problems recipes develop slowly in the USA and several other drug take a look at ends in the corporate’s pipeline are greater than anticipated, added G -Ja Subject. President Trump’s elections have additionally weighed pharmaceutical firms as a complete towards the background of potential adjustments to well being coverage.
There was a “very uncertainty,” she mentioned, as traders have nervous extra about whether or not overweight drug gross sales can actually be meet the high expectations of the industry From the market, greater than $ 100 billion within the coming a long time. Novo Nordisk’s The main racer is the American drug maker Eli Lilywho additionally sells weight problems medicines.
On Wednesday Nova Nordisk mentioned his Revenue jumped 25 percent last year As much as $ 290 billion Kroner, or $ 40.6 billion, led by rising gross sales in the USA, and reported a revenue of over 100 billion Danish kroner.
It expects gross sales development from 16 to 24 % in 2025, lower than the earlier yr, because of elevated competitors and value strain. However the firm mentioned it nonetheless sees a robust seek for therapy for weight problems.
“The variety of overweight individuals could be very, very giant, so it is a market that we’re simply beginning to serve,” says Lars Freergard Jogensen, CEO of medication, on Wednesday’s name. The management for 2025 accepts a “quite vital ramp” in gross sales in the USA, he added.
The price of the corporate’s shares elevated about 5 % on Wednesday.
Novo Nordisk has been repeatedly inserted into the highlight in latest weeks by G -N -Trump and its new administration.
Robert F. Kennedy, Jr., who mentioned he didn’t like weight problems medicine, was the nominee for G -N Trump’s Well being Secretary, a publication that may give him to provide him some force above entry to remedy. And final month, d -n Trump Threatened tariffs in Denmark, the native country of Novo Nordiskin spitting over Greenland. Novo Nordisk producers of a few of its medicines in the USA, however nonetheless imports the energetic pharmaceutical ingredient, semi -glyde, for a few of its hottest injection medicines.
Karsten Males Knudsen, Chief Monetary Officer of the corporate, mentioned in an interview on Wednesday that the corporate has numerous optimism for 2025. However “we’re not naive about every part that’s occurring round us,” he added. “Geopolitics might be extra variable than what has been in the previous couple of years.”
Over the previous couple of weeks, threats and tariff imposition has created nice uncertainty for enterprise leaders around the globe. Though d -n Trump postponed the charges of products from Canada and Mexico this week, he continued with further tariffs for Chinese language items and warned that The European Union’s tariffs “definitely happen”.
NEW NORDISK started this yr to recuperate from Disappointing sample results From its subsequent era for weight reduction medication. After a late -stage take a look at barely missed the expectations, the corporate’s inventory value was immersed by 20 % in at some point on the finish of December. However Jogensen mentioned that the corporate stays “assured in Cagrashma’s biology”.
Novo Nordisk additionally mentioned he expects to use for Cagrisema’s first regulatory approval in early 2026. Final month, take a look at outcomes at a brand new stage of a brand new drug, Amycretin, carried out effectively, pushing the corporate’s shares.
